Asimov, based in Boston, provides engineered host cells, genetic parts and design software that help companies develop and make biologics, cell and gene therapies and RNA medicines.
At a glance
| Price from | Custom |
| Best for | Drug developers improving cell lines and genetic designs |
From Asimov's own website.
What stands out
- Combines cell engineering and design software
- Focused on medicine manufacturing
Worth knowing
- Serves drug developers only
- Price set per programme
How it ranks
Asimov is ranked 8th of 10 in Best Synthetic Biology Companies (Lister Score 87.8).
#8 in Best Synthetic Biology Companies · Lister Score 87.8
Asimov announced $200 million in financing, including a $175 million Series B, in January 2023..
| Rank | Best Synthetic Biology Companies | Score |
|---|---|---|
| 1 | Novonesis | 97.2 |
| 2 | Ginkgo Bioworks | 95.9 |
| 3 | Twist Bioscience | 94.6 |
| 4 | LanzaTech | 93.2 |
| 5 | Solugen | 91.9 |
| 6 | Pivot Bio | 90.5 |
| 7 | Spiber | 89.2 |
| 8 | Asimov | 87.8 |
| 9 | Arzeda | 86.3 |
| 10 | Modern Meadow | 84.9 |
Frequently asked questions
How does Asimov rank on Lister?
Asimov is ranked 8th of 10 in Best Synthetic Biology Companies (Lister Score 87.8).
Appears in
Add this badge to your site
If you work at Asimov, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.